- Home
- OBE vs ZURA Comparison
OBE vs ZURA Comparison
Compare OBE & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBE | ZURA |
|---|---|---|
| Founded | 1979 | 2022 |
| Country | Canada | United States |
| Employees | N/A | 30 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.9M | 521.8M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | OBE | ZURA |
|---|---|---|
| Price | $9.74 | $5.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $10.00 | ★ $11.78 |
| AVG Volume (30 Days) | ★ 907.9K | 552.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.88 | $0.99 |
| 52 Week High | $9.81 | $7.25 |
Technical Indicators
Market Signals| Indicator | OBE | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 70.50 | 44.01 |
| Support Level | $5.57 | $5.49 |
| Resistance Level | N/A | $5.75 |
| Average True Range (ATR) | 0.40 | 0.48 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 98.34 | 37.78 |
Price Performance
Historical ComparisonAbout OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Sale of Oil.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.